A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors

Summary

The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, and pharmacokinetics (PK) to determine the maximum tolerated dose (MTD) and/or preliminary recommended dose for expansion (RDE) of NKT3447 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and the preliminary antitumor activity of NKT3447 in adult subjects with cyclin E1 (CCNE1) amplified ovarian cancer at the RDEs selected in Dose Escalation and to determine the preliminary recommended phase 2 dose (RP2D).

Timeline

Start

2024-02-23

Primary completion

2025-04-07

Completion

2025-04-16

Outcome

Outcome not reported

Stopped (Business): “This study was terminated as a result of Sponsor portfolio reprioritization.”

Drugs

Indications